









Markets
/
Stocks
/
nasdaq-srrk
/

Scholar Rock Holding Corp

SRRK

47.620USD

+3.170+7.13%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.72BMarket Cap

LossP/E TTM



Scholar Rock Holding Corp

47.620

+3.170+7.13%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Scholar Rock Holding Corp

Currency: USD Updated: 2026-02-06

Key Insights

Scholar Rock Holding Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 27 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.36.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Scholar Rock Holding Corp's Score

Industry at a Glance

Industry Ranking

27 / 392

Overall Ranking

122 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Scholar Rock Holding Corp Highlights

StrengthsRisks

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -15.12, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 123.29M shares, increasing 0.97% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 24.95K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.42.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

49.357

Target Price

+5.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Scholar Rock Holding Corp is 6.32, ranking 267 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.32

Change



Financials

7.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.68

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Scholar Rock Holding Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Scholar Rock Holding Corp is 6.68, ranking 238 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -15.12, which is -84.91% below the recent high of -2.28 and -28.31% above the recent low of -19.40.

Score

Industry at a Glance

Previous score

6.68

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Scholar Rock Holding Corp is 8.88, ranking 42 out of 392 in the Biotechnology & Medical Research industry. The average price target is 47.50, with a high of 53.00 and a low of 42.00.

Score

Industry at a Glance

Previous score

8.88

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

49.357

Target Price

+5.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Scholar Rock Holding Corp

SRRK

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Scholar Rock Holding Corp is 9.35, ranking 15 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 51.42 and the support level at 42.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.41

Change

1.94

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.204

Buy

RSI(14)

57.075

Neutral

STOCH(KDJ)(9,3,3)

54.588

Neutral

ATR(14)

2.532

High Vlolatility

CCI(14)

80.653

Neutral

Williams %R

31.655

Buy

TRIX(12,20)

0.192

Sell

StochRSI(14)

71.143

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

46.692

Buy

MA10

45.473

Buy

MA20

45.207

Buy

MA50

44.538

Buy

MA100

38.937

Buy

MA200

36.343

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Scholar Rock Holding Corp is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 120.87%, representing a quarter-over-quarter decrease of 2.15%. The largest institutional shareholder is PRFDX, holding a total of 6.78M shares, representing 6.65% of shares outstanding, with 28.28% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

13.96M

+1.27%

Invus Public Equities Advisors, LLC

9.25M

T. Rowe Price Associates, Inc.

Star Investors

6.78M

-21.72%

Samsara BioCapital, LLC

5.80M

+3.39%

BlackRock Institutional Trust Company, N.A.

5.68M

-0.36%

The Vanguard Group, Inc.

Star Investors

4.90M

+1.10%

Wellington Management Company, LLP

4.55M

+124.50%

Redmile Group, LLC

3.90M

-0.63%

State Street Investment Management (US)

3.76M

+22.41%

Bellevue Asset Management AG

3.24M

+10.09%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Scholar Rock Holding Corp is 4.72, ranking 72 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.71. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.